Daniel James George, MD

Professor of Medicine
Professor in Surgery
Member of the Duke Cancer Institute
Campus mail Duke Box 103861, Durham, NC 27710
Phone (919) 668-4615
Email address daniel.george@duke.edu

Education and Training

  • Fellow in Medical Oncology, Medicine, Johns Hopkins University, 1995 - 1998
  • Medical Resident, Medicine, Johns Hopkins University, 1992 - 1995
  • M.D., Duke University, 1992

Grants

Publications

Szymaniak, Brittany M., Lauren A. Facchini, Veda N. Giri, Emmanuel S. Antonarakis, Tomasz M. Beer, Maria I. Carlo, Daniel C. Danila, et al. “Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC.” Jco Oncol Pract 16, no. 12 (December 2020): 811–19. https://doi.org/10.1200/OP.20.00431.

PMID
32986533
Full Text

Powers, Eric, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong, and Tian Zhang. “Novel therapies are changing treatment paradigms in metastatic prostate cancer.” J Hematol Oncol 13, no. 1 (October 28, 2020): 144. https://doi.org/10.1186/s13045-020-00978-z.

PMID
33115529
Full Text

Zhang, Tian, Michael R. Harrison, Peter H. O’Donnell, Ajjai S. Alva, Noah M. Hahn, Leonard J. Appleman, Jeremy Cetnar, et al. “A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer.” Cancer 126, no. 20 (October 15, 2020): 4485–97. https://doi.org/10.1002/cncr.33067.

PMID
32757302
Full Text

Patel, Anup, Alain Ravaud, Robert J. Motzer, Allan J. Pantuck, Michael Staehler, Bernard Escudier, Jean-François Martini, Mariajose Lechuga, Xun Lin, and Daniel J. George. “Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial.” Clin Cancer Res 26, no. 18 (September 15, 2020): 4863–68. https://doi.org/10.1158/1078-0432.CCR-20-0704.

PMID
32546645
Full Text

Bu, Jiyoon, Ashita Nair, Luke J. Kubiatowicz, Michael J. Poellmann, Woo-Jin Jeong, Marco Reyes-Martinez, Andrew J. Armstrong, et al. “Surface engineering for efficient capture of circulating tumor cells in renal cell carcinoma: From nanoscale analysis to clinical application.” Biosens Bioelectron 162 (August 15, 2020): 112250. https://doi.org/10.1016/j.bios.2020.112250.

PMID
32392161
Full Text

Rencsok, Emily M., Latifa A. Bazzi, Rana R. McKay, Franklin W. Huang, Adam Friedant, Jake Vinson, Samuel Peisch, et al. “Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions.” Cancer Epidemiol Biomarkers Prev 29, no. 7 (July 2020): 1374–80. https://doi.org/10.1158/1055-9965.EPI-19-1616.

PMID
32503813
Full Text

Zhang, Tian, Sarabjot Pabla, Felicia L. Lenzo, Jeffrey M. Conroy, Mary K. Nesline, Sean T. Glenn, Antonios Papanicolau-Sengos, et al. “Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients.” Oncoimmunology 9, no. 1 (June 10, 2020): 1773200. https://doi.org/10.1080/2162402X.2020.1773200.

PMID
32923131
Full Text

Shore, Neal D., Fred Saad, Michael S. Cookson, Daniel J. George, Daniel R. Saltzstein, Ronald Tutrone, Hideyuki Akaza, et al. “Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.” N Engl J Med 382, no. 23 (June 4, 2020): 2187–96. https://doi.org/10.1056/NEJMoa2004325.

PMID
32469183
Full Text

Bakthavatsalam, Subha, Petpailin Wiangnak, Daniel J. George, Tian Zhang, and Katherine J. Franz. “Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer.” Bioorg Med Chem Lett 30, no. 11 (June 1, 2020): 127148. https://doi.org/10.1016/j.bmcl.2020.127148.

PMID
32253061
Full Text

Pages